One Technology Place
234 articles about EMD Serono
EMD Serono and Pfizer Inc. announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® alone or as part of combination regimens for the treatment of advanced cancers, including renal cell carcinoma, metastatic Merkel cell carcinoma and some other solid tumors at the European Society for Medical Oncology Congress 2019 in Barcelona, Spain.
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC)
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton's Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Company to present 39 abstracts, including data on MAVENCLAD® tablets, Rebif® and investigational evobrutinib
Agreement will grant EMD Serono access to genomic data for drug research
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from its multiple sclerosis (MS) portfolio at the Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting, taking place May 28 – June 1, 2019 in Seattle, WA.
EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD® (cladribine) tablets, which was approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019.
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS)
She will serve as a member of EMD Serono's leadership team, as well as a member of the Global Compliance Healthcare team led by Betania Glorio, Global Compliance Officer, Healthcare, Merck KGaA, Darmstadt, Germany.
The incubator will be located at Merck Serono's current facilities in Yavne, a town in central Israel.
Merck Serono As Pioneer In Assisted Reproductive Treatments Takes Leading Role In Fertility Technologies Signing A Global Collaboration Agreement With Genea Biomedx
Intrexon Corporation And Merck Serono Announce Agreement For The Development And Commercialization Of CAR-T Therapy
Illumina Announces Strategic Collaboration With Merck Serono To Expand Companion Diagnostics For Oncology